LYRA
Lyra Therapeutics, Inc. (LYRA) Economic Moat Analysis (2026)
Overall Score
Pricing Power
Gross margin remains 100%, but the company still posts deeply negative operating and net margins, indicating no durable pricing power at the operating level.
Revenue per share is only 0.03 while price-to-sales is 0.89, suggesting the business is still not monetizing scale effectively.
Cost Advantage
Operating expenses remain extremely heavy, with SG&A at 28.7% of revenue and R&D at 46.3% of revenue, leaving margins deeply negative.
Asset turnover is only 0.01 and fixed-asset turnover is 0.02, showing very weak operating efficiency.
Switching Costs
No evidence of customer lock-in or recurring revenue durability is visible in the financials.
The company continues to generate negative operating cash flow and negative free cash flow, which does not support a switching-cost moat.
Network Effects
There is no financial evidence of network-driven scale benefits or self-reinforcing user growth.
Low revenue generation and persistent losses suggest the business has not yet reached a network-effect flywheel.
Intangible Assets
Gross margin at 100% may indicate some IP or product differentiation, but it is not translating into sustainable profitability.
R&D intensity is high at 46.3% of revenue, yet returns on capital remain deeply negative, implying the intangible base is not yet a moat.
Efficient Scale
The company is still too small and loss-making to demonstrate efficient-scale advantages.
Negative returns on invested capital and capital employed indicate no evidence of a protected niche with excess returns.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lyra Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

